Pablo Tolosa

Pablo Tolosa

Auto-generated profile, based on publicly available information

Pablo Tolosa


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
APAleix Prat
Aleix Prat
FBFara Brasó-Maristany
Fara Brasó-Maristany
OMOlga Martínez-Sáez
Olga Martínez-Sáez
ESEsther Sanfeliu
Esther Sanfeliu
YXYouli Xia
Youli Xia
AVAna Vivancos
Ana Vivancos
Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the ability of plasma ctDNA to capture complex tumor phenotypes with clinical value is unknown. To address this question, we have performed 0.5X shallow whole-genome sequencing in plasma from 459 patients with metastatic breast cancer, including 245 patients treated with endocrine therapy and a CDK4/6 inhibitor (ET + CDK4/6i) from 2 independent cohorts. We demonstrate that machine learning multi-gene signatures, obtained from ctDNA, identify complex biological features, including measures of tumor proliferation and estrogen receptor signaling, similar to what is accomplished using direct tumor tissue DNA or RNA profiling. More importantly, 4 DNA-based subtypes, and a ctDNA-based genomic signature tracking retinoblastoma loss-of-heterozygosity, are significantly associated with poor response and survival outcome following ET + CDK4/6i, independently of plasma tumor fraction. Our approach opens opportunities for the discovery of additional multi-feature genomic predictors coming from ctDNA in breast cancer and other cancer-types.

1 August 2021 in The Breast
Verified
Journal Article
Open access
MGMiguel Gil-Gil
Miguel Gil-Gil
EAEmilio Alba
Emilio Alba
JGJoaquín Gavilá
Joaquín Gavilá
JHJuan de la Haba-Rodríguez
Juan de la Haba-Rodríguez
ECEva Ciruelos
Eva Ciruelos
ALANTONIO LLOMBART-CUSSAC
ANTONIO LLOMBART-CUSSAC
The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.

25 April 2025 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
RSRodrigo Sánchez-Bayona
Rodrigo Sánchez-Bayona
OMOlga Martínez-Sáez
Olga Martínez-Sáez
DRDenys Romero-Romero
Denys Romero-Romero
ESElia Seguí
Elia Seguí
ECEsther Carcelero
Esther Carcelero
APAleix Prat
Aleix Prat
In advanced HER2-positive breast cancer, the standard taxane-trastuzumab-pertuzumab (THP) regimen faces competition from new therapies, emphasizing the need for biomarkers to guide treatment. This study evaluates the HER2DX ERBB2 mRNA score as a prognostic predictor, aiming to tailor treatment strategies. We retrospectively analyzed 94 patients treated with the THP regimen between 2010 and 2024. The HER2DX ERBB2 mRNA score was categorized as low (n = 14), medium (n = 20), or high (n = 60), and its correlation with progression-free survival (PFS) and overall survival (OS) was assessed using Cox regression models. The median follow-up was 31.5 months. Patients with ERBB2-high scores had significantly better median PFS (33.9 vs. 10.6 months, hazard ratio [HR] = 0.40, 95% CI: 0.24–0.69, p < 0.001) and OS (not reached vs. 30.8 months, HR = 0.26, 95% CI: 0.13–0.49, p < 0.001) compared to ERBB2-low patients. Based on these findings, further validation of this biomarker in tumor samples from the CLEOPATRA phase III trial is ongoing, which could help optimize treatment strategies in this population.

1 April 2024 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
NMN. Martínez-Jañez
N. Martínez-Jañez
Meritxell BelletMeritxell Bellet
Meritxell Bellet
LSL. M. Manso Sanchez
L. M. Manso Sanchez
FHFernando Henao-Carrasco
Fernando Henao-Carrasco
AAAntonio Antón
Antonio Antón
FMFernando Moreno-Anton
Fernando Moreno-Anton
Purpose: To evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval.Methods: PALBOSPAIN is an observational, retrospective, multicenter study evaluating real-world patterns and outcomes with 1 L palbociclib in men and women (any menopausal status) with advanced HR+/HER2– BC diagnosed between November 2017 and November 2019. The primary endpoint was real-world progression-free survival (rw-PFS). Secondary endpoints included overall survival (OS), the real-world response rate (rw-RR), the clinical benefit rate, palbociclib dose reduction, and safety.Results: A total of 762 patients were included. The median rw-PFS and OS were 24 months (95% CI 21–27) and 42 months (40-not estimable [NE]) in the whole population, respectively. By cohort, the median rw-PFS and OS were as follows: 28 (95% CI 23–39) and 44 (95% CI 38-NE) months in patients withde novometastatic disease, 13 (95% CI 11–17) and 36 months (95% CI 31–41) in patients who experienced relapse < 12 months after the end of ET, and 31 months (95% CI 26–37) and not reached (NR) in patients who experienced relapse > 12 months after the end of ET. rw-PFS and OS were longer in patients with oligometastasis and only one metastatic site and those with non-visceral disease. The most frequent hematologic toxicity was neutropenia (72%; grade ≥ 3: 52.5%), and the most common non-hematologic adverse event was asthenia (38%).Conclusion: These findings, consistent with those from clinical trials, support use of palbociclib plus ET as 1 L for advanced BC in the real-world setting, including pre-menopausal women and men.Trial registration number: NCT04874025 (PALBOSPAIN). Date of registration: 04/30/2021 retrospectively registered.

4 January 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
PTPablo Tolosa
Pablo Tolosa
TPTomás Pascual
Tomás Pascual
OMOlga Martínez-Saez
Olga Martínez-Saez
CHCristina Hernando
Cristina Hernando
SSSonia Servitja
Sonia Servitja
ECEva Maria Ciruelos
Eva Maria Ciruelos

1 December 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
Mafalda OliveiraMafalda Oliveira
Mafalda Oliveira
ECEva Maria Ciruelos
Eva Maria Ciruelos
GVGuillermo Villacampa
Guillermo Villacampa
SMSerafin Morales
Serafin Morales
JSJavier Salvador-Bofill
Javier Salvador-Bofill
CMCristina Saura Manich
Cristina Saura Manich
Purpose: The aim of this study was to evaluate the safety and feasibility of ipatasertib combined with trastuzumab and pertuzumab (HP) as maintenance therapy after first-line treatment in patients with HER2-positive metastatic breast cancer harboring PIK3CA mutations (PIK3CAmut). Patients and Methods: This prospective, multicenter, single-arm, phase Ib study evaluated the safety and preliminary efficacy of ipatasertib, an AKT inhibitor, combined with HP, with or without endocrine therapy as maintainance therapy, in patients with unresectable locally advanced or metastatic PIK3CAmut, HER2-positive breast cancer following first-line induction chemotherapy and HP. Results: Seventeen patients were enrolled, with a median follow-up of 27.7 months. During the dose-selection phase, ipatasertib at 400 mg daily (21 days on and 7 days off) with standard HP was established as the recommended phase II dosage. This decision was based on the absence of dose-limiting toxicities in the first six patients treated at this dosage during the initial 28-day cycle, which constituted the primary endpoint. Grade 3 treatment-related adverse events (TRAE) occurred in seven patients (41.2%), most commonly diarrhea and nausea. Two (11.8%) reported four serious TRAE (diarrhea, vomiting, ischemic stroke, and pneumonitis, one case each) related to ipatasertib, from which they recovered. The confirmed overall response rate was 31.1% [95% confidence interval (CI), 12.1%–58.5%], clinical benefit rate 84.6% (95% CI, 53.7%–97.3%), and median progression-free survival 16.4 months (95% CI, 9.4–NR); 47.3% of patients were progression free at 18 months. Conclusions: These results support ipatasertib plus HP as a safe and promising maintenance strategy for HER2-positive breast tumors harboring PIK3CAmut.